Literature DB >> 6122264

Depressive states occurring during the neuroleptic treatment of schizophrenia.

H J Möller, D von Zerssen.   

Abstract

Depressive states are often observed during the hospitalizations of acutely schizophrenic patients. But only a few studies have examined the frequency and course pattern of these depressions. In our investigation of 81 patients suffering from schizophrenic or paranoid psychoses and undergoing neuroleptic treatment, we found that the frequency and intensity of depression decreased from admission to discharge. On admission, 63 percent of patients showed a marked depressive apathetic syndrome, as compared to only 23 percent on discharge. Patients' self-rating data from the Actual Mood Scale (filled out every other day) showed that only a small proportion of the patients developed a depression during hospitalization without having also been depressed on admission. An analysis of psychiatrists' admission and discharge ratings produced similar results. Our findings suggest tht neuroleptics are unlikely to be the major cause of depressions in patients suffering from acute schizophrenic or paranoid psychoses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122264     DOI: 10.1093/schbul/8.1.109

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

Review 1.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 2.  Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations.

Authors:  Max Birchwood; Zaffer Iqbal; Rachel Upthegrove
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 3.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

4.  A linear mathematical model for computerized analyses of mood curves. An empirical investigation on mood courses in depressive and schizophrenic inpatients.

Authors:  H J Möller; M Leitner; T Dietzfelbinger
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

5.  The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity.

Authors:  Hans-Jürgen Möller; Markus Jäger; Michael Riedel; Michael Obermeier; Anton Strauss; Ronald Bottlender
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-05-22       Impact factor: 5.270

6.  Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations.

Authors:  G Alfredsson; C Härnryd; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany.

Authors:  B Bandelow; P Müller; U Frick; W Gaebel; M Linden; F Müller-Spahn; A Pietzcker; J Tegeler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

8.  Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich.

Authors:  B Bandelow; P Müller; W Gaebel; W Köpcke; M Linden; F Müller-Spahn; A Pietzcker; F M Reischies; J Tegeler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

Review 9.  Depression in schizophrenia: current guidelines to treatment.

Authors:  S J Bartels; R E Drake
Journal:  Psychiatr Q       Date:  1989

Review 10.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.